Despite treatment modification to reduce toxicity, similar results are a longstanding feature of IL-2 treatment for cancer, including pediatric tumors (Roper et al., 1992), renal cell carcinoma (Clark et al., 1999; Lee et al., 2010; Moroni et al., 2000), non–small cell lung cancer (Ardizzoni et al., 1994), neuroblastoma (Pardo et al., 1996), mesothelioma (Nano et al., 1998), and melanoma (Cragun et al., 2005; Woodson et al., 2004), with eosinophilia in treated patients being predictive of treatment failure (Moroni et al., 2000). This evidence concerns the gene IL2 and neuroblastoma.